Apotex raises C$1.3bn in Canada's largest IPO since 2021
The generic drugmaker priced at the top of its C$20-24 range and upsized the offering on strong demand, making it Canada's biggest listing in five years. SK Capital Partners, which acquired Apotex from the murdered Sherman family estate for US$3 billion in 2023, is using most proceeds to pay down C$800 million in debt. The company reported C$3.5 billion revenue and C$374 million earnings last year, implying a mid-single-digit earnings multiple typical for generics. The successful pricing could revive Canada's dormant IPO market after years of TSX neglect.
Sources
- Apotex IPO Canada — Bloomberg
- Apotex TSX IPO — Globe and Mail
How Briefed reports and verifies storiesReport a correction
The market, before the open.
Briefed Daily connects the morning’s business and economic news to what matters in markets.